{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:55:58Z","timestamp":1788285358330,"version":"build-2803163510"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T00:00:00Z","timestamp":1561075200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T00:00:00Z","timestamp":1561075200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s40620-019-00622-1","type":"journal-article","created":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T13:02:27Z","timestamp":1561122147000},"page":"673-675","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Homocysteine and chronic kidney disease: an ongoing narrative"],"prefix":"10.1093","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4048-9392","authenticated-orcid":false,"given":"Alessandra F.","family":"Perna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Ingrosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,6,21]]},"reference":[{"issue":"1","key":"622_CR1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/00075197-200401000-00010","volume":"78","author":"AF Perna","year":"2004","unstructured":"Perna AF, Ingrosso D, Satta E et al (2004) Homocysteine metabolism in renal failure. Curr Opin Clin Nutr Metab Care 78(1):53\u201357","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"6","key":"622_CR2","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1093\/ndt\/gfv409","volume":"31","author":"AF Perna","year":"2016","unstructured":"Perna AF, Ingrosso D (2016) Atherosclerosis determinants in renal disease: How much is homocysteine involved ? Nephrol Dial Transplant 31(6):860\u2013863","journal-title":"Nephrol Dial Transplant"},{"issue":"175","key":"622_CR3","first-page":"177","volume":"14","author":"D Murphy","year":"2019","unstructured":"Murphy D, Drawz PE (2019) Blood pressure variability in CKD. Treatable or hypertension\u2019s homocysteine? Clin J Am Soc Nephrol 14(175):177","journal-title":"Clin J Am Soc Nephrol"},{"key":"622_CR4","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.kint.2016.09.019","volume":"90","author":"CM Wyatt","year":"2016","unstructured":"Wyatt CM, Spence JD (2016) Folic acid supplementation and chronic kidney disease progression. Kidney Int 90:1144\u20131145","journal-title":"Kidney Int"},{"issue":"3","key":"622_CR10","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3945\/jn.114.207589","volume":"145","author":"R Obeid","year":"2015","unstructured":"Obeid R (2015) Serum unmetabolized folic acid: the straw that broke dihydrofolate reductase\u2019s back ? J Nutr 145(3):387\u2013390","journal-title":"J Nutr"},{"issue":"13","key":"622_CR5","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1001\/jama.2015.2274","volume":"313","author":"Y Huo","year":"2015","unstructured":"Huo Y, Li J, Qin X, CSPPT Investigators, et al (2015) Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial. JAMA 313(13):1325\u20131335","journal-title":"JAMA"},{"issue":"10","key":"622_CR6","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1001\/jamainternmed.2016.4687","volume":"176","author":"X Xu","year":"2016","unstructured":"Xu X, Qin X, Li Y et al (2016) Efficacy of folic acid therapy on the progression of chronic kidney disease: the renal substudy of the china stroke primary prevention trial. JAMA Intern Med. 176(10):1443\u20131450","journal-title":"JAMA Intern Med."},{"key":"622_CR7","doi-asserted-by":"crossref","unstructured":"Cohen E, Margalit I, Shochat T et al (2019) The relationship between the concentration of plasma homocysteine and chronic kidney disease. J Nephrol doi: 10.1007\/s40620-019-00618-x","DOI":"10.1007\/s40620-019-00618-x"},{"key":"622_CR8","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1093\/ndt\/gfv380","volume":"31","author":"JD Spence","year":"2016","unstructured":"Spence JD, Urquhart BL, Bang H (2016) Effect of renal impairment on atherosclerosis: only partially mediated by homocysteine. Nephrol Dial Transplant 31:937\u2013944","journal-title":"Nephrol Dial Transplant"},{"key":"622_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20092269","author":"C Vigorito","year":"2019","unstructured":"Vigorito C, Anishchenko E, Mele L et al (2019) Uremic toxin lanthionine interferes with the transsulfuration pathway, angiogenetic signaling and increases intracellular calcium. Int J Mol Sci. \n                    https:\/\/doi.org\/10.3390\/ijms20092269","journal-title":"Int J Mol Sci"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-019-00622-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40620-019-00622-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-019-00622-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:56:11Z","timestamp":1777564571000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/32\/5\/673\/8328171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,21]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["622"],"URL":"https:\/\/doi.org\/10.1007\/s40620-019-00622-1","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,21]]},"assertion":[{"value":"6 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Author AFP has received research funding from Gnosis spa, and EUTox.\u00a0DI holds a 3rd mission collaboration with Gnosis, spa through a contract stipulated with the Department of Precision Medicine, University \u201cLuigi Vanvitelli\u201d.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}